Analysts predict that OptiNose, Inc. (NASDAQ:OPTN – Get Rating) will announce earnings per share of ($0.23) for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for OptiNose’s earnings, with the highest EPS estimate coming in at ($0.22) and the lowest estimate coming in at ($0.24). OptiNose reported earnings per share of ($0.49) in the same quarter last year, which suggests a positive year over year growth rate of 53.1%. The company is scheduled to issue its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that OptiNose will report full year earnings of ($0.77) per share for the current financial year, with EPS estimates ranging from ($0.87) to ($0.72). For the next fiscal year, analysts forecast that the business will report earnings of ($0.24) per share, with EPS estimates ranging from ($0.34) to ($0.14). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for OptiNose.
OptiNose (NASDAQ:OPTN – Get Rating) last issued its quarterly earnings results on Tuesday, March 8th. The company reported ($0.23) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.26) by $0.03. During the same quarter in the prior year, the business posted ($0.46) earnings per share.
Shares of OptiNose stock opened at $2.54 on Tuesday. OptiNose has a 52-week low of $1.46 and a 52-week high of $3.92. The stock has a market capitalization of $209.34 million, a price-to-earnings ratio of -1.72 and a beta of 0.51. The company has a fifty day moving average of $2.58 and a 200-day moving average of $2.33.
In other news, CEO Peter K. Miller sold 25,974 shares of the company’s stock in a transaction on Wednesday, March 16th. The shares were sold at an average price of $2.11, for a total value of $54,805.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 38,810 shares of company stock valued at $81,889 in the last ninety days. 6.00% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. Buckingham Strategic Wealth LLC purchased a new stake in OptiNose during the 4th quarter valued at $26,000. Citadel Advisors LLC purchased a new stake in OptiNose during the 3rd quarter valued at $53,000. D. E. Shaw & Co. Inc. boosted its position in OptiNose by 159.8% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 37,066 shares of the company’s stock valued at $60,000 after buying an additional 22,797 shares during the period. Goldman Sachs Group Inc. boosted its position in OptiNose by 83.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 55,318 shares of the company’s stock valued at $90,000 after buying an additional 25,140 shares during the period. Finally, Hsbc Holdings PLC boosted its position in OptiNose by 71.3% during the 3rd quarter. Hsbc Holdings PLC now owns 37,336 shares of the company’s stock valued at $110,000 after buying an additional 15,541 shares during the period. 62.31% of the stock is owned by institutional investors and hedge funds.
About OptiNose (Get Rating)
OptiNose, Inc operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.
- Get a free copy of the StockNews.com research report on OptiNose (OPTN)
- 3 Undervalued Easter Eggs to Watch For This Earnings Season
- Lululemon Rises On Wave Of Price Target Increases
- The Top Is In For Infosys
- Is Nvidia (NASDAQ: NVDA) About To Rip Higher?
- 3 Stellar Steel Stocks to Buy Now
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.